1093 related articles for article (PubMed ID: 28404110)
1. Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial.
Waked I; Shiha G; Qaqish RB; Esmat G; Yosry A; Hassany M; Soliman R; Mohey MA; Allam N; Zayed N; Asselah T; Hall C; Redman R; Mobashery N; Doss W
Lancet Gastroenterol Hepatol; 2016 Sep; 1(1):36-44. PubMed ID: 28404110
[TBL] [Abstract][Full Text] [Related]
2. Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial.
Asselah T; Hézode C; Qaqish RB; ElKhashab M; Hassanein T; Papatheodoridis G; Feld JJ; Moreno C; Zeuzem S; Ferenci P; Yu Y; Redman R; Pilot-Matias T; Mobashery N
Lancet Gastroenterol Hepatol; 2016 Sep; 1(1):25-35. PubMed ID: 28404108
[TBL] [Abstract][Full Text] [Related]
3. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial.
Hézode C; Asselah T; Reddy KR; Hassanein T; Berenguer M; Fleischer-Stepniewska K; Marcellin P; Hall C; Schnell G; Pilot-Matias T; Mobashery N; Redman R; Vilchez RA; Pol S
Lancet; 2015 Jun; 385(9986):2502-9. PubMed ID: 25837829
[TBL] [Abstract][Full Text] [Related]
4. Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial.
Welzel TM; Asselah T; Dumas EO; Zeuzem S; Shaw D; Hazzan R; Forns X; Pilot-Matias T; Lu W; Cohen DE; Feld JJ
Lancet Gastroenterol Hepatol; 2017 Jul; 2(7):494-500. PubMed ID: 28416221
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis.
Lawitz E; Makara M; Akarca US; Thuluvath PJ; Preotescu LL; Varunok P; Morillas RM; Hall C; Mobashery N; Redman R; Pilot-Matias T; Vilchez RA; Hézode C
Gastroenterology; 2015 Oct; 149(4):971-80.e1. PubMed ID: 26170136
[TBL] [Abstract][Full Text] [Related]
6. Ombitasvir/Paritaprevir/Ritonavir: A Review in Chronic HCV Genotype 4 Infection.
Keating GM
Drugs; 2016 Aug; 76(12):1203-11. PubMed ID: 27401997
[TBL] [Abstract][Full Text] [Related]
7. Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study.
Petta S; Marzioni M; Russo P; Aghemo A; Alberti A; Ascione A; Antinori A; Bruno R; Bruno S; Chirianni A; Gaeta GB; Giannini EG; Merli M; Messina V; Montilla S; Perno CF; Puoti M; Raimondo G; Rendina M; Silberstein FC; Villa E; Zignego AL; Pani L; Craxì A; ;
Lancet Gastroenterol Hepatol; 2017 Jun; 2(6):427-434. PubMed ID: 28497758
[TBL] [Abstract][Full Text] [Related]
8. Ombitasvir/paritaprevir/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection.
Klibanov OM; Gale SE; Santevecchi B
Ann Pharmacother; 2015 May; 49(5):566-81. PubMed ID: 25680759
[TBL] [Abstract][Full Text] [Related]
9. Change in the hepatic profile of hepatitis C virus genotype 4-infected patients with compensated cirrhosis receiving ombitasvir, paritaprevir, and ritonavir plus ribavirin: A subanalysis of the AGATE-II study.
Waked I; Esmat G; Fouad R; Allam N; Hassany M; Mohey M; Shiha G; Soliman R; Qaqish RB; Hall C; Alami NN; Kopecky-Bromberg S; Mobashery N
J Med Virol; 2018 Nov; 90(11):1739-1744. PubMed ID: 29900553
[TBL] [Abstract][Full Text] [Related]
10. Randomized Phase 3 Trial of Ombitasvir/Paritaprevir/Ritonavir and Ribavirin for Hepatitis C Virus Genotype 2-Infected Japanese Patients.
Sato K; Chayama K; Alves K; Toyoda H; Suzuki F; Kato K; Rodrigues L; Zhang X; Setze C; Pilot-Matias T; Burroughs M; Redman R; Kumada H
Adv Ther; 2017 Jun; 34(6):1449-1465. PubMed ID: 28536999
[TBL] [Abstract][Full Text] [Related]
11. Ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin for chronic hepatitis C virus genotype 1b-infected cirrhotics (TURQUOISE-IV).
Isakov V; Paduta D; Viani RM; Enejosa JV; Pasechnikov V; Znoyko O; Ogurtsov P; Bogomolov PO; Maevskaya MV; Chen X; Shulman NS
Eur J Gastroenterol Hepatol; 2018 Sep; 30(9):1073-1076. PubMed ID: 29762255
[TBL] [Abstract][Full Text] [Related]
12. Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks.
Feld JJ; Moreno C; Trinh R; Tam E; Bourgeois S; Horsmans Y; Elkhashab M; Bernstein DE; Younes Z; Reindollar RW; Larsen L; Fu B; Howieson K; Polepally AR; Pangerl A; Shulman NS; Poordad F
J Hepatol; 2016 Feb; 64(2):301-307. PubMed ID: 26476290
[TBL] [Abstract][Full Text] [Related]
13. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.
Poordad F; Hezode C; Trinh R; Kowdley KV; Zeuzem S; Agarwal K; Shiffman ML; Wedemeyer H; Berg T; Yoshida EM; Forns X; Lovell SS; Da Silva-Tillmann B; Collins CA; Campbell AL; Podsadecki T; Bernstein B
N Engl J Med; 2014 May; 370(21):1973-82. PubMed ID: 24725237
[TBL] [Abstract][Full Text] [Related]
14. Real-world safety and efficacy of paritaprevir/ritonavir/ombitasvir plus dasabuvir ± ribavirin in patients with hepatitis C virus genotype 1 and advanced hepatic fibrosis or compensated cirrhosis: a multicenter pooled analysis.
Chen CH; Chen CH; Lin CL; Lin CY; Hu TH; Tung SY; Hsieh SY; Lu SN; Chien RN; Hung CH; Sheen IS
Sci Rep; 2019 May; 9(1):7086. PubMed ID: 31068655
[TBL] [Abstract][Full Text] [Related]
15. Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy.
Grebely J; Conway B; Cunningham EB; Fraser C; Moriggia A; Gane E; Stedman C; Cooper C; Castro E; Schmid P; Petoumenos K; Hajarizadeh B; Marks P; Erratt A; Dalgard O; Lacombe K; Feld JJ; Bruneau J; Daulouede JP; Powis J; Bruggmann P; Matthews GV; Kronborg I; Shaw D; Dunlop A; Hellard M; Applegate TL; Crawford S; Dore GJ;
Int J Drug Policy; 2018 Dec; 62():94-103. PubMed ID: 30384028
[TBL] [Abstract][Full Text] [Related]
16. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection.
Andreone P; Colombo MG; Enejosa JV; Koksal I; Ferenci P; Maieron A; Müllhaupt B; Horsmans Y; Weiland O; Reesink HW; Rodrigues L; Hu YB; Podsadecki T; Bernstein B
Gastroenterology; 2014 Aug; 147(2):359-365.e1. PubMed ID: 24818763
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial.
Lawitz E; Gane E; Pearlman B; Tam E; Ghesquiere W; Guyader D; Alric L; Bronowicki JP; Lester L; Sievert W; Ghalib R; Balart L; Sund F; Lagging M; Dutko F; Shaughnessy M; Hwang P; Howe AY; Wahl J; Robertson M; Barr E; Haber B
Lancet; 2015 Mar; 385(9973):1075-86. PubMed ID: 25467591
[TBL] [Abstract][Full Text] [Related]
18. Retreatment Efficacy of Sofosbuvir/Ombitasvir/Paritaprevir/Ritonavir + Ribavirin for Hepatitis C Virus Genotype 4 Patients.
Abdel-Moneim A; Aboud A; Abdel-Gabbar M; Zanaty M; Ramadan M
Dig Dis Sci; 2018 May; 63(5):1341-1347. PubMed ID: 29546644
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials.
Lawitz E; Buti M; Vierling JM; Almasio PL; Bruno S; Ruane PJ; Hassanein TI; Muellhaupt B; Pearlman B; Jancoriene L; Gao W; Huang HC; Shepherd A; Tannenbaum B; Fernsler D; Li JJ; Grandhi A; Liu H; Su FH; Wan S; Dutko FJ; Nguyen BT; Wahl J; Robertson MN; Barr E; Yeh WW; Plank RM; Butterton JR; Yoshida EM
Lancet Gastroenterol Hepatol; 2017 Nov; 2(11):814-823. PubMed ID: 28802814
[TBL] [Abstract][Full Text] [Related]
20. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.
Feld JJ; Kowdley KV; Coakley E; Sigal S; Nelson DR; Crawford D; Weiland O; Aguilar H; Xiong J; Pilot-Matias T; DaSilva-Tillmann B; Larsen L; Podsadecki T; Bernstein B
N Engl J Med; 2014 Apr; 370(17):1594-603. PubMed ID: 24720703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
